Introduction Malignant pleural effusion (MPE) affects up to 15% of patients with cancer, and its incidence and prevalence are increasing. 1 - 4 Most cases are symptomatic; the most common symptoms are ...

The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ...

Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line ...

Patients with malignant pleural mesothelioma are diagnosed at advanced stages and have limited treatment options. Patients with coexpression of ERCC1 and RPM1 in tumor tissues exhibited significantly ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Nearly one in five patients with malignant pleural mesothelioma (MPM) at a Barcelona hospital contracted COVID-19 during the pandemic. In addition, those patients suffered a 75% mortality rate, ...

The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination ...